1


Board -2023 -Mtg -04 -Doc 01e -Annex M
Report to the Board
6-7 December 2023

Annex M: Comparison of Key Commercial Terms in the Proposed Amendment

December 2022 executed agreement December 2023 amendment
Size $US 1 billion (max $350m outstanding
at any one time)
Same
Partners US DFC Same
Duration 2 years to draw funds; final repayment
by 15 December 2026
4 years to draw funds; final repayment
by 15 December 2030
Eligible
donors
Sovereign nations with A - or better
long -term credit rating or satisfactory
(to DFC) corporations, foundations or
philanthropic organisations
Same
Collateral 50% of the value of undocumented
pledges;
66.7% of the value of outstanding
signed grant agreements; and cash
deposited in the secured collection
account
Same
Recourse Limited recourse to Gavi
• No recourse to Gavi balance
sheet for repayment of
principal, except in the case of
certain breaches of the
agreement (relating to a
prohibited use of proceeds, or
breach of compliance
obligations)
• Gavi will be obligated to pay
interest, expenses above
$90,000 and claims under the
indemnity
Same
Use of funds • 83 AMC countries
• C19 vaccines +/or associated
costs (no cap on mix between
the two)
• Chinese & Russian vaccines
excluded
• 83 countries
• C19 vaccines +/or routine
vaccines + associated
costs (no cap on mix)
• Potential to finance novel
vaccines subject to additional
acceptability criteria to be
mutually agreed at the time of
a future outbreak
• Chinese & Russian vaccines
excluded

Annex C: 10 existing IRC members proposed to be
exceptionally extended to a third term
1 Board Meeting, 6 - 7 December 2023Members currently serving a second term to be exceptionally extended for an additional three - year term
# Name Nationality Gender Expertise
1. Jean Marc Olive France Male Fragility, NVS, M/MR
2. Jean Rostand Kamga Côte d'Ivoire Male Finance & budget
3. John Crump New Zealand Male NVS, TCV, Outbreaks
4. Kondwani Msampha Malawi Male HSS, Finance & budget
5. Lisa Cairns Canada Female NVS, M/MR
6. Natasha Howard Canada Female Fragility, NVS, HPV, Malaria
7. Toagoe Karzon Liberia Male Finance & budget
8. Viviana Mangiaterra Italy Female NVS, Malaria, HSS
9. Vivien Tsu USA Female NVS, HPV
10. Wassim Khrouf Tunisia Male Finance & budget
Members bring experience in areas of key strategic focus for Gavi’s 5.1 strategy,
including HPV, malaria and financial cross - cutting skills that were not sufficiently
replenished during the 2023 recruitment.
Doc 01e - Annex C

1 | P a g e December 2022 2023
BOARD AND BOARD COMMITTEE
OPERATING PROCEDURES
Purpose and definitions
These Operating Procedures apply to the governance, administrative and advisory bodies
as list e d in Article 8 of the Statutes . Unless defined in these Operating Procedures all
capitalised terms used in these Operating Procedures shall have the meaning given to
such terms in the Statutes (as amended from time to time). Section mean s sections of
these Operating Procedures. “Business day” means a working day in the Canton of Geneva.
Board
1. Appointment Process
1.1. The Board has formed a “ Governance Committee ” responsible, among other
things, for recommending the appointment of qualified candidates to the
Board in accordance with the Statutes a nd these Operating Procedures.
1.2. The Governance Committee duties, whether or not delegated to another Board
C ommittee (as defined in Section 1 8 ) or a sub - committee, shall be subject to
the provisions of Section 1 8 .
1.3. The Governance Committee shall recommend the nomination of candidates for
Board membership in accordance with the procedures herein.
1.4. The Governance Committee may establish, subject to Board approval,
additional procedures with respect to the designation and nomination of
Board members as are reasonably necessary to carry out these provisions.
1.5. The Governance Committee may establish, subject to the approval of the
Board, minimum criteria as to the qualifications and competencies of all Board
members, provided such criteria shall not unreasonably restrict or interfere
with the right of any Eligible Organisation or Eligible Constituency to select its
Board member(s) according to its Selection Process. The criteria for B oard
membership shall be consistent with the guiding principles on gender for
Board and Board Committee nominations.
Doc 01e - Annex E

Annex A: Thirteen new members proposed to add to IRC
expert pool
1 Board Meetiing, 6 - 7 December 2023Members identified through transparent recruitment process initiated in August 2023
# Name Current position French -
speaking Nationality Gender Expertise
1 Juliana Ajuma Amanyi -
Enegela Sr Programme Manager NTDs, Christian
Blind Mission Nigeria Female HSS, Finance & budget
2 Julie Pasquier Independent Consultant X France Female Finance & budget, CCL
3 Ngo Bibaa Lundi - Anne
Omam Independent Consultant X Cameroon Female Fragility, HSS, Data & M&E, pro - equity &
gender, Finance & budget
4 Natalie McCall Associate Professor of Pediatrics.
University of Rwanda X Switzerland Female NVS
5 Pierre de Vasson Supply Chain Director, Bee Skilled X France Male HSS, Finance & budget, CCL
6 Sehrish Tehreem Telemedicine Physician, Sehat Kahani Pakistan Female NVS, Data & M&E, pro - equity & gender
7 Mutuku Stephen Mutinda Policy and Planning Specialist, Kenya
National Aids Control Council Kenya Male Finance & budget
8 Tony Chahale Mugasia Independent Consultant Kenya Male HPV, Malaria
9 Antony Ngatia Programme Director, Vaccines and Digital
Health, CHAI Kenya Male NVS, HSS
10 Wangara Tidiani Independent Consultant X Mali Male Fragility, Finance & budget
11 Eric - Didier N'Dri Economic Security Delegate, International
Committee of the Red Cross X Cote d'Ivoire Male Fragility, Cholera, HSS
12 Chioma Nwuba Sr Procurement & Supply Management
Expert PriceWaterhouse Coopers Nigeria Female CCL
13 Akram Ali Eltoum Mohamed Sr Programe Development Consultant,
Project Hope X Egypt Male Fragility, HSS Doc 01e - Annex A

Annex B: 25 existing IRC members proposed to be
extended to a second term
1 Board Meeting, 6 - 7 December 2023Members currently serving a first term to be extended for an additional three - year term
# Name Nationality Gender Expertise
1. Alima (Tene) Essoh Côte d'Ivoire Female NVS, HPV, Campaigns, HSS
2. Anne McArthur - Lloyd UK Female NVS, HPV
3. Barbara Johnson USA Female Lab
4. Beatriz Ayala - Öström Mexico Female Fragility, Malaria, CCL, HSS
5. Beena Varghese India Female NVS, Data, M&E, Finance & budget, HSS
6. Bolanle Oyeledun Nigeria Female HPV, Data, M&E, HSS
7. Borja Cuervo Alonso Spain Male Fragility, pro - equity & gender, HSS
8. Femi Oyewole Nigeria Male Fragility, HSS
9. Gavin Surgey South Africa Male Finance & budget, HSS
10. Giorgi Pkhakadze Georgia Male Data, M&E, HSS, HSS
11. Helen Saxenian USA Female Fragility, NVS, Finance & budget
12. Joanne Thomson Australia Female Pro - equity & gender
13. Joses Kirigia Kenya Male Data, M&E, Finance & budget
14. Kate Gallagher UK Female NVS, HPV
15. Linda O'Neal Eckert USA Female NVS, M/MR, HPV
16. Mohamed Dramé Guinea Male Fragility, HSS
17. Ousmane Amadou Sy Senegal Male HSS, finance & budget
18. Ousmane Dia Senegal Male Fragility, HSS, CCL
19. Oyewale T. Tomori Nigeria Male Fragility, pro - equity & gender
20. Pat Taylor USA Female HSS
21. Pierre Corneille Namahoro Rwanda Male Fragility, HSS, CCL
22. Sabine Beckmann Germany Female Fragility, Campaigns/SIA, HSS, pro - equity & gender
23. Teklay Desta Ethiopia Male NVS, M/MR, Data & M&E
24. Tippi Mak Canada Female NVS, pro - equity & gender
25. Valerie Chambard France Female CCL Doc 01e - Annex B

This document aims to address: 1. Introduce real-time monitoring approaches and how RTM can strengthen vaccination campaigns and routine immunization programmes; 2. Provide guidance to decision-makers and planners on the key considerations enabling implementation of real time approaches and digital solutions in order to strengthen vaccination campaigns and routine immunization programmes, thereby enhancing immunization service delivery; 3. Elaborate on implementation aspects related to realtime monitoring technologies.

This country technical brief presents three use cases of Real-Time Monitoring (RTM) approaches used in Rwanda for 1) COVID-19 surveillance 2) Vaccination Delivery and Monitoring and 3) COVID-19 case management. Good practices and lessons learned by Rwanda are also highlighted in the brief.